Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | SNCA | P37840 | 9/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | USP25 | Q9UHP3 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7222939 | 0.90 | TRPV1 (0.43) | TRPV1SNCALMNAL3MBTL1KMT2A | |
| SCHEMBL7231259 | 0.85 | TRPV1 (0.48) | TRPV1SNCALMNAL3MBTL1USP25 | |
| SCHEMBL7224296 | 0.84 | TRPV1 (0.46) | TRPV1SNCA | |
| SCHEMBL7232847 | 0.83 | HAT1 (0.52) | TRPV1SNCALMNAL3MBTL1USP25 | |
| SCHEMBL7222496 | 0.83 | TRPV1 (0.46) | TRPV1SNCALMNAL3MBTL1ITGB3 | |
| SCHEMBL7224015 | 0.82 | TRPV1 (0.44) | TRPV1SNCALMNAL3MBTL1KMT2A | |
| SCHEMBL7222215 | 0.82 | TRPV1 (0.47) | TRPV1SNCALMNAL3MBTL1KMT2A | |
| SCHEMBL7224364 | 0.82 | HAT1 (0.47) | TRPV1SNCALMNAL3MBTL1KMT2A | |
| SCHEMBL7231452 | 0.80 | TRPV1 (0.46) | TRPV1SNCALMNAL3MBTL1POLB | |
| SCHEMBL7222947 | 0.79 | SNCA (0.60) | SNCAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6541505-B1 | Inhibiting the activity of Factor Xa; treating a disease state associated with a physiologically detrimental excess amount of thrombin. | AVENTIS PHARMACEUTICALS INC. | 2003-04-01 | — | — | US | claimed |
| US-6541505-B1 | Inhibiting the activity of Factor Xa; treating a disease state associated with a physiologically detrimental excess amount of thrombin. | AVENTIS PHARMACEUTICALS INC. | 2003-04-01 | — | — | US | disclosed |